Newsstand Menu

A new treatment approach for cystic fibrosis

X-Ray Scan of Human Chest
An X-ray of a pair of lungs. Cystic fibrosis is a genetic disorder that leads to chronic lung congestion and infection, among other symptoms. Image: © wittybear -
Print Friendly, PDF & Email

Antisense oligonucleotides, or ASOs, are molecules that can be used to control protein levels in cells. Cold Spring Harbor Laboratory Professor Adrian Krainer leveraged ASO technology to develop the first FDA-approved treatment for spinal muscular atrophy called Spinraza®. The drug has helped over 11,000 patients make more of a protein that certain neurons in the spine need.

Since then, Krainer has been searching for more ways ASOs can help treat other disorders. He has zeroed in on cystic fibrosis (CF), where patients do not make enough of a protein called CFTR. His team discovered how to use ASOs to make more of an imperfect but still functional version of CFTR. The discovery sets the stage for a new therapeutic approach that may help reduce CF symptoms and improve patients’ quality of life.

The imperfect CFTR protein is a result of a gene mutation. It causes cells to receive the wrong instructions for making the protein. The faulty instructions are eliminated and the protein isn’t made, since in general, imperfect proteins may be disruptive. Krainer’s ASOs trick cells into following the faulty instructions and making the imperfect CFTR protein. His team found that, in this case of CF, having an imperfect version of the protein is better than having none at all. Their method improved the function of lung cells, suggesting the ASO strategy could improve symptoms in CF patients with this mutation.

The team’s discovery spotlights a new way ASOs can be used to treat disease. The study was led by Young Jin Kim, a former M.D.-Ph.D. student in the Krainer laboratory. Krainer hopes to continue expanding the potential of ASO technology in therapeutics. He thinks in the future ASOs may increasingly become a way to tailor therapies specific to an individual’s unique genetic mutations. “If more of this type of drug, ASOs, are approved,” Krainer says, “I wouldn’t be surprised if in the not-so-distant future ASOs become a routine way to make personalized medicines.”

Written by: Luis Sandoval, Communications Specialist | | 516-367-6826


Print Friendly, PDF & Email

Cystic Fibrosis Foundation, National Institutes of Health, National Cancer Institute


Print Friendly, PDF & Email

Kim, Y.J., et al., “Gene-Specific Nonsense-Mediated mRNA Decay Targeting for Cystic Fibrosis Therapy”, Nature Communications, May 27, 2022. DOI: 10.1038/s41467-022-30668-y

Stay informed

Sign up for our newsletter to get the latest discoveries, upcoming events, videos, podcasts, and a news roundup delivered straight to your inbox every month.

  Newsletter Signup

Principal Investigator

Adrian R. Krainer

Adrian R. Krainer

St. Giles Foundation Professor
Cancer Center Deputy Director of Research
Ph.D., Harvard University, 1986